Quanterix Corporation · NASDAQ:QTRX
Quanterix — Q3 2022 Earnings Presentation
10 slides from Quanterix's earnings presentation, Nov 8, 2022
Slide 1: Q3 2022 Earnings Call
Q3 2022 Earnings Call November 8, 2022
Slide 2: Forward-Looking Statements & Pro-Forma Financial Measures
Forward-Looking Statements & Pro-Forma Financial Measures This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as we
Slide 3: Progress on Assay Redevelopment Roadmap
Progress on Assay Redevelopment Roadmap Q2 2022 Q3 2022 Q4 2022 H1 2023 H2 2023 CEO transition on Strategic review Stability and Manufacturing Process automation April 25th completed in July, variance improve implementation of Process scaling Business strategic business ments for prima
Slide 4: Q3 2022 Revenue results are aligned with company expectations
Q3 2022 Revenue results are aligned with company expectations Reiterate full year 2022 revenue to be flat compared to 2021 $105M (excluding one time '21 NIH grant funding) Q 3 G AAP Q 3 Pr of or m a 2021 2022 2021 2022 OTHER INSTRUMENTS CONSUM ABLES ACCELERATOR ADDF/ RADx SERVICES 27.7 27.7 Revenue
Slide 5: Q3 2022 Cash & Cash Burn
Q3 2022 Cash & Cash Burn -17.5 $m 363.9Cash Balance & Cash Usage 0.4 3.7 346.3 35.1 20.8 End Q2 2022 Net Loss Non Working CAPEX End Q3 FY22 Cash Activities Capital and Others 5
Slide 6: Reconciliation of GAAP to Pro Forma
Reconciliation of GAAP to Pro Forma Quanterix Corporation Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (Unaudited and in thousands, except percentages) Three Months Ended Three Months Nine Months Ended September 30, Ended June 30, September 30, 2022 2021 2022 2022 2021 GA
Slide 7: Supplemental Schedule of Operating Expenses
Supplemental Schedule of Operating Expenses Quanterix Corporation Supplemental Schedule of Operating Expenses (Unaudited and in thousands) Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Operating expenses: Research and development $ 6,631 $ 6,807 $ 20,290 $ 20,2
Slide 8: Scientific Validation Driving Adoption
Scientific Validation Driving Adoption Neurology Immunology & Oncology Infectious Diseases Others 2022 Advances PUBLICATIONS BIOMARKERS INSTRUMENTS Cumulative Cumulative Placements 532 # of units placed Cumulative 837 2,004 45 480 125 93 41 46 212 708 403 44 1,575 73 186 113 319 177 322 535 168 1,12
Slide 9: New Simoa NfL Publications: Key Biomarker to Assess Neural Damage
New Simoa NfL Publications: Key Biomarker to Assess Neural Damage Stroke Monitoring Traumatic Brain Injury Therapy and Recovery Correlation with symptoms Ref. 1. Ref.4. CAR - (T) Therapy Side effect monitoring (ICANS) NfL Secondary End Point New Therapeutics Ref. 2. Ref. 5. Chemotherapy Multiple Scl
Slide 10: Alzheimer's: Blood Biomarkers Increasingly Utilized in Clinical Trials
Alzheimer’s: Blood Biomarkers Increasingly Utilized in Clinical Trials Accelerants for efficiency & effectiveness: 1 Pre-screening/enrollment of larger, more diverse populations with decrease screen fails 3 Monitoring of drug effects (pharmacodynamic) 2 Improved targeting along the disease continuum